Advertisement
NeuroScientistNews
NeuroScientistNews

Genome patent overturned

Yesterday the British High Court overturned a UK genome patent owned by biotech Human Genome Sciences. The patent covered the inflammation-linked protein neutrokine-alpha which is part of the tumor necrosis factor family of cytokines. The court overturned the patent, ruling that at the time its application was filed there was no practical application, the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/c2649894-5f54-11dd-91c0-000077b07658.html?nclick_check=1 Human Genome Science

By | August 1, 2008

Yesterday the British High Court overturned a UK genome patent owned by biotech Human Genome Sciences. The patent covered the inflammation-linked protein neutrokine-alpha which is part of the tumor necrosis factor family of cytokines. The court overturned the patent, ruling that at the time its application was filed there was no practical application, the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/c2649894-5f54-11dd-91c0-000077b07658.html?nclick_check=1 Human Genome Sciences applied for the patent in the mid-1990s. But the ruling might really affect Eli Lilly, who has spent $50 million developing an antibody to neutrokine-alpha and is looking to spend another $250 million bringing the therapy through clinical trials, the Times reported.
Advertisement

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
The Scientist
The Scientist

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
The Scientist
The Scientist
Advertisement
The Scientist
The Scientist
Life Technologies